Fig. 6: Effects of S63845 and imatinib administered as single drug or in combination on the apoptotic rate of the parental K562 line and its imatinib resistant sublines harboring the T315I mutation in BCR-ABL1. | Cell Death & Disease

Fig. 6: Effects of S63845 and imatinib administered as single drug or in combination on the apoptotic rate of the parental K562 line and its imatinib resistant sublines harboring the T315I mutation in BCR-ABL1.

From: Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells

Fig. 6

Proportion of active caspase-3/7 positive cells in the parental K562 line and its T315I mutation harboring sublines left untreated or treated for 60 h with 50 nM S63845 in the absence or presence of the indicated concentrations of imatinib, analyzed by fluorescence live cell microscopy. Data represent mean with standard deviation derived from three technical replicates. Experiments were performed at least twice with similar results.

Back to article page